Amarin Corp PLC/ US0231112063 /
2024-05-06 10:00:00 PM | Chg. +0.0700 | Volume | Bid1:58:37 AM | Ask1:58:37 AM | High | Low |
---|---|---|---|---|---|---|
0.9800USD | +7.69% | 1.66 mill. Turnover: 1.57 mill. |
0.9620Bid Size: 200 | 0.9800Ask Size: 700 | 1.0200 | 0.9000 |
GlobeNewswire
04-24
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate P...
GlobeNewswire
04-15
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
GlobeNewswire
04-08
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
GlobeNewswire
04-06
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular...
GlobeNewswire
04-03
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
GlobeNewswire
03-25
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American ...
GlobeNewswire
02-29
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
02-15
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February...
GlobeNewswire
01-10
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For ...
GlobeNewswire
2023-12-04
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Oth...
GlobeNewswire
2023-11-12
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Red...
GlobeNewswire
2023-10-31
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
GlobeNewswire
2023-10-26
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Land...
GlobeNewswire
2023-10-19
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023